Table 1. Detection and prognostic relevance of CTCs in ovarian cancer.
| Authors (year) | Study Type |
No. of Patients | Timing | Capture Method | Detection Method | Targeted Antigen/Gene |
Positive Rate (%) |
Prognostic Significance |
|---|---|---|---|---|---|---|---|---|
| Marth et al. (2002) [20] | Case Series |
90 | Before adjuvant chemotherapy | Immunomagnetic (Dynabeads®) | ICC | MOC-31 | 12.0 | NS |
| Kurata et al. (2002) [21] | Case Series |
24 | Not mentioned | Not separated | RT-PCR | CK7, CK20 | 46 | Not mentioned |
| Sapi et al. (2002) [23] | Case Series |
28 | Before any therapy | Immunomagnetic | ICC | HEA-125, CD45 | 75 | NS |
| Judson et al. (2003) [24] | Case Series |
59 | Before surgery | Immunomagnetic beads | ICC | CK8 and 18, TFS-2, CK7, CK20, EGFR | 18.7 | NS |
| Oikonomopoulou et al. (2006) [25] | Case Series |
24 | Before and after therapy | Immunomagnetic separation | RT-PCR | Kallikreins, BER-EP4 | 75 | NS |
| Wimberger et al. (2007) [26] | Case Series |
57 | 57 before therapy & 45 after therapy | Density gradient | ICC | A45-B/B3 , CK8, 18, 19 | 21 | NS |
| He et al. (2008) [22] | Case Series |
20 | Not mentioned | Density gradient | Flow cytometry | Folate-AlexaFluor 488 & DUPA-FITC |
90 | NS |
| Fan et al. (2009) [6] | Case Series |
66 | Before surgery | CAM+ functional enrichment | ICC | EpCAM; CK 4, 5, 6, 8, 10, 13 and 18 | 60.6 | NS |
| Behbakht et al. (2011) [27] | Phase II Clinical | 54 | Before and after Temsirolimus | Immunomagnetic (CellSearch) | ICC (CellSearch) | EpCAM | 44.0 (bef cycle 1) | NS |
| Poveda et al. (2011) [11] | Phase III Clinical | 216 | Before 2nd line chemotherapy | Immunomagnetic (CellSearch) | ICC (CellSearch) | EpCAM; CK8, 18 and 19 | 14.4 | NS |
| Aktas et al. (2011) [7] | Case Series |
122 | Before surgery and/or after chemotherapy | Immunomagnetic (Adnatest) | RT-PCR (Adnatest) | EpCAM, MUC-1, CA-125 HER-2 |
19.0 (bef surgery) 27.0 (after CT) |
HR = 4.56 (1.94–10.73) p = 0.05 |
| Liu et al. (2013) [28] | Case Series |
30 new 48 recurrent |
Before chemotherapy | Immunomagnetic (CellSearch) | ICC (CellSearch) | EpCAM | 60.0 new 53.8 recurrent |
NS |
| Obermayr et al. (2013) [17] | Case Series |
216 | Before surgery & after adjuvant chemotherapy | Density gradient centrifugation RNA extraction (Qiacube system) | RT-PCR | PPIC, GPX8, CDH3, TUSC3, COL3A1, LAMB1, MAM, ESRP2, AGR2, BAIAP2L1, TFF1, EpCAM | 24.5 (bef surgery) 20.4 (after CT) |
HR = 2.3 (1.1–4.8) p = 0.024 |
| Pearl et al. (2014) [4] | Case Series |
88 | Before surgery | CAM (functional enrichment) | ICC | EpCAM, CA-125, DPP4 & CKs |
88.6 | HR = 1.06 (0.41–2.73) p = 0.0219 |
| Kuhlmann et al. (2014) [12] | Case Series |
143 | Before surgery | Immunomagnetic (Adnatest) | RT-PCR (Adnatest) | EpCAM, MUC1, MUC6, ERCC1 | 14.0 | HR = 1.85 (1.03–3.32) p = 0.041 |
| Ning N et al. (2014) [16] | Case Series |
141 | Before and 7th day after surgery | Immunomagnetic beads-CD45 | FISH (centromere probe 8) ICC | CD45, CK | 76.2 | Not mentioned |
| Kolostova et al. (2015) [29] | Case Series |
118 | Before surgery | MetaCell | CM/RT-PCR | MUC1, EpCAM, CA125 | 65.2 | NS |
| Kolostova et al. (2016) [30] | Case Series |
56 | Before surgery | MetaCell | ICC | - | 58 | Not mentioned |
| This article | Case Series |
30 patients 31 controls |
Before surgery | Size-based microfluidic separation | ICC | EpCAM, panCK, CK7, Vimentin and HE4 | 73.3 |
NS: No Significance.